Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Lupus nephritis (LN) remains a leading cause of morbidity and mortality in systemic lupus erythematosus, with marked heterogeneity in presentation and outcomes. While histological class and serological activity predict renal prognosis, the influence of demographic and socioeconomic factors on treatment response and infection burden remains poorly defined, particularly in Indian cohorts.
An ambispective, single-center study was conducted at AIIMS, New Delhi, including 242 biopsy-proven LN patients (2018–2023). Demographic, socioeconomic (Modified Kuppuswamy 2018), clinical, biochemical, immunological, and histopathological parameters were recorded. Patients were followed for a mean of 22.8 months. Outcomes included remission, end stage renal disease (ESRD), infections and mortality.
The cohort (mean age 29.6 ± 9.5 years; 87.2% female) predominantly belonged to the upper-lower socioeconomic stratum (71.1%). Class IV was the most frequent histological subtype (40.9%) followed by class V (24%). Mucocutaneous features and arthritis were frequent extra-renal manifestations. At baseline, mean eGFR was 95.6 ml/min/1.73 m², proteinuria was 2.7 g/day and the average SLEDAI was 17.3. Cyclophosphamide was used in 35% and mycophenolate mofetil in 58% for induction, with MMF used in 84% for maintenance. At follow up, 50% achieved complete remission, 20% partial remission and 29% had no remission. End stage renal disease developed in 10%, infections in 26% and death in 5%. Poor outcomes were associated with hypertension, antiphospholipid antibody positivity, higher disease activity indices, low complement and elevated dsDNA. Higher eGFR, hemoglobin and serum albumin, and lower proteinuria were associated with better prognosis. Socio-economic class did not significantly influence remission or complications.
This large cohort highlights that while classical clinical and immunopathological factors remain central to LN prognosis, lower socioeconomic status predisposes to higher infection rates rather than direct renal deterioration. Optimizing infection prevention, patient education, and access to healthcare is critical for improving outcomes in resource-limited settings.
